Ozbalak, M. Et Al. 2020. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. ANNALS OF HEMATOLOGY , vol.99 , 301-307.

Ozbalak, M., SALİHOĞLU, A., Soysal, T., Karadogan, I., PAYDAŞ, S., Ozdemir, E., ... Yildiz, B.(2020). Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. ANNALS OF HEMATOLOGY , vol.99, 301-307.

Ozbalak, Murat Et Al. "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience," ANNALS OF HEMATOLOGY , vol.99, 301-307, 2020

Ozbalak, Murat Et Al. "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience." ANNALS OF HEMATOLOGY , vol.99, pp.301-307, 2020

Ozbalak, M. Et Al. (2020) . "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience." ANNALS OF HEMATOLOGY , vol.99, pp.301-307.

@article{article, author={Murat Ozbalak Et Al. }, title={Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience}, journal={ANNALS OF HEMATOLOGY}, year=2020, pages={301-307} }